<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40916703</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0844</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>08</Day></PubDate></JournalIssue><Title>European journal of heart failure</Title><ISOAbbreviation>Eur J Heart Fail</ISOAbbreviation></Journal><ArticleTitle>Sacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy with heart failure: Baseline characteristics of the PARACHUTE-HF trial.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/ejhf.70026</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">The PARACHUTE-HF trial (NCT04023227) is evaluating the effect of sacubitril/valsartan compared with enalapril on a hierarchical composite of cardiovascular events (cardiovascular death, first heart failure hospitalization), and change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in participants with heart failure and reduced ejection fraction (HFrEF) caused by chronic Chagas cardiomyopathy (CCC). We describe the baseline characteristics of participants in PARACHUTE-HF compared with prior HFrEF trials.</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">PARACHUTE-HF, a multicentre, active-controlled, open-label trial, enrolled 922 participants with confirmed CCC, New York Heart Association (NYHA) functional class II-IV, and left ventricular ejection fraction (LVEF) &#x2264;40%. Participants were randomized 1:1 to sacubitril/valsartan (97/103&#x2009;mg bid) or enalapril (10&#x2009;mg bid). Enrolled participants (mean age: 64.2&#x2009;years, 42.0% women) had a baseline LVEF of 29.8% (NYHA class II: 61.7%; NHYA class III/IV: 38.2%). History included hypertension (40.5%), atrial fibrillation/flutter (32.5%), ventricular arrhythmia (24.7%) and stroke (12.5%). The majority of patients had cardiac conduction abnormalities and 46.0% had conventional pacemaker, cardiac resynchronization therapy or implantable cardioverter-defibrillator. Mean systolic blood pressure was 118&#x2009;mmHg, and median NT-proBNP level was 1730&#x2009;pg/ml.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Baseline characteristics of this study highlight the unique clinical profile of patients with CCC-related HFrEF, including the high proportion of women affected, lower rates of comorbidities (hypertension/diabetes) and higher prevalence of stroke and pacemaker implantation when compared with other non-CCC-related HFrEF studies. These findings reinforce the need for dedicated heart failure treatments in this neglected subpopulation, particularly in Latin America where Chagas disease remains a significant public health issue.</AbstractText><CopyrightInformation>&#xa9; 2025 European Society of Cardiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Echeverria</LastName><ForeName>Luis Eduardo</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3;n Cardiovascular de Colombia, Universidad de Santander, Floridablanca, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bocchi</LastName><ForeName>Edimar</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Heart Failure Clinics, Instituto do Cora&#xe7;&#xe3;o (InCor), Hospital das Clinicas da Faculdade de Medicina da Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demacq</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><Identifier Source="ORCID">0009-0003-5823-1135</Identifier><AffiliationInfo><Affiliation>Novartis Pharma AG, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Barros E Silva</LastName><ForeName>Pedro Gabriel Melo</ForeName><Initials>PGM</Initials><AffiliationInfo><Affiliation>Brazilian Clinical Research Institute (BCRI), S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiang</LastName><ForeName>Lu-May</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Novartis Pharma AG, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sayyed</LastName><ForeName>Sarfaraz</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Novartis Pharma AG, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Damiani</LastName><ForeName>Lucas Petri</ForeName><Initials>LP</Initials><AffiliationInfo><Affiliation>Brazilian Clinical Research Institute (BCRI), S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbosa</LastName><ForeName>Lilian Mazza</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Brazilian Clinical Research Institute (BCRI), S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furtado</LastName><ForeName>Remo Holanda de Mendon&#xe7;a</ForeName><Initials>RHM</Initials><AffiliationInfo><Affiliation>Brazilian Clinical Research Institute (BCRI), S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morillo</LastName><ForeName>Carlos A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Libin Cardiovascular Institute, University of Calgary, Calgary, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kevorkian</LastName><ForeName>Ruben</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Hospial D.F. Santojanni, Buenos Aires University, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramires</LastName><ForeName>Felix</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Heart Failure Clinics, Instituto do Cora&#xe7;&#xe3;o (InCor), Hospital das Clinicas da Faculdade de Medicina da Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bahit</LastName><ForeName>Maria Cecilia</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>INECO Neurociencias Oro&#xf1;o, Rosario, Argentina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Baim Institute for Clinical Research, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chavez-Mendoza</LastName><ForeName>Adolfo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hospital de Cardiologia, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maga&#xf1;a-Serrano</LastName><ForeName>Jos&#xe9; Antonio</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Hospital de Cardiologia, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carbajales</LastName><ForeName>Justo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hospital Ramos Mejia, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliveira Junior</LastName><ForeName>Wilson</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Pronto-Socorro Cardiol&#xf3;gico da Universidade de Pernambuco, Recife, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molina</LastName><ForeName>Israel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Postgraduate Program in Health Sciences, State University of Montes Claros, Montes Claros, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Vall d'Hebron University Hospital, PROSICS Barcelona; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freitas Junior</LastName><ForeName>Arguinaldo F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Universidade Federal de Goi&#xe1;s, Goiania, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreira</LastName><ForeName>Maria da Consola&#xe7;ao</ForeName><Initials>MDC</Initials><AffiliationInfo><Affiliation>Felicio Rocho Hospital, Belo Horizonte, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Adegil Henrique</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Instituto de Cardiologia e Transplantes do Distrito Federal do Distrito Federal, Brasilia, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva Junior</LastName><ForeName>Telemaco</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Eurolatino Pesquisas Medicas, Uberl&#xe2;ndia, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saporito</LastName><ForeName>Wladimir</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Pesquisare Saude, Santo Andr&#xe9;, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerr Saraiva</LastName><ForeName>Jos&#xe9; Francisco</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Clinical Research Institute of Campinas, Campinas, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gimpelewicz</LastName><ForeName>Claudio</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Novartis Pharma AG, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McMurray</LastName><ForeName>John J V</ForeName><Initials>JJV</Initials><AffiliationInfo><Affiliation>British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopes</LastName><ForeName>Renato Delascio</ForeName><Initials>RD</Initials><Identifier Source="ORCID">0000-0003-2999-4961</Identifier><AffiliationInfo><Affiliation>Brazilian Clinical Research Institute (BCRI), S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Duke University School of Medicine, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>&#x2009;on behalf of the PARACHUTE&#x2010;HF Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Novartis It is a Novartis Sponsored Study</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Heart Fail</MedlineTA><NlmUniqueID>100887595</NlmUniqueID><ISSNLinking>1388-9842</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chagas disease</Keyword><Keyword MajorTopicYN="N">Chronic Chagas cardiomyopathy</Keyword><Keyword MajorTopicYN="N">HFrEF</Keyword><Keyword MajorTopicYN="N">Neglected tropical disease</Keyword><Keyword MajorTopicYN="N">Sacubitril/valsartan</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>8</Day><Hour>4</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40916703</ArticleId><ArticleId IdType="doi">10.1002/ejhf.70026</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Cousin E, Nascimento BR, Collaborators, GBD, Investigators, RAISE, Mosser J, Ribeiro, ALP. Global, Regional, and National Burden of Chagas Disease, 1990&#x2010;2023: A Systematic Analysis for the Global Burden of Disease Study 2023 (June 18, 2025). Available at SSRN: https://ssrn.com/abstract=5381800 or https://doi.org/10.2139/ssrn.5381800</Citation></Reference><Reference><Citation>Bocchi EA, Bestetti RB, Scanavacca MI, Cunha Neto E, Issa VS. Chronic Chagas heart disease management: From etiology to cardiomyopathy treatment. J Am Coll Cardiol 2017;70:1510&#x2013;1524. https://doi.org/10.1016/j.jacc.2017.08.004</Citation></Reference><Reference><Citation>Franca EB, Ishitani LH, Carneiro M, Machado IE, Nascimento BR, Martins&#x2010;Melo FR, et al. Chagas disease deaths detected among garbage codes registered in mortality statistics in Brazil: A study from the buRden of ChAgas dISEase in the contemporary world (RAISE) project. Public Health 2024;227:112&#x2013;118. https://doi.org/10.1016/j.puhe.2023.11.034</Citation></Reference><Reference><Citation>Nascimento BR, Naback ADN, Santos BMP, Geissb&#xfc;hler Y, Demacq C, Quijano M, et al.; RAISE Investigators. Prevalence of clinical forms of Chagas disease: A systematic review and meta&#x2010;analysis&#xa0;&#x2013;&#xa0;data from the RAISE study. Lancet Reg Health Am 2024;30:100681. https://doi.org/10.1016/j.lana.2024.100681</Citation></Reference><Reference><Citation>Benziger CP, Do Carmo GAL, Ribeiro ALP. Chagas cardiomyopathy: Clinical presentation and management in the Americas. Cardiol Clin 2017;35:31&#x2013;47. https://doi.org/10.1016/j.ccl.2016.08.013</Citation></Reference><Reference><Citation>Echeverria LE, Serrano&#x2010;Garcia AY, Rojas LZ, Berrios&#x2010;B&#xe1;rcenas EA, G&#xf3;mez&#x2010;Mesa JE, et al. Mechanisms behind the high mortality rate in chronic Chagas cardiomyopathy: Unmasking a three&#x2010;headed monster. Eur J Heart Fail 2024;26:2502&#x2013;2514. https://doi.org/10.1002/ejhf.3460</Citation></Reference><Reference><Citation>Shen L, Ramires F, Martinez F, Bodanese LC, Echeverr&#xed;a LE, G&#xf3;mez EA, et al.; PARADIGM&#x2010;HF and ATMOSPHERE Investigators and Committees. Contemporary characteristics and outcomes in Chagasic heart failure compared with other nonischemic and ischemic cardiomyopathy. Circ Heart Fail 2017;10:e004361. https://doi.org/10.1161/CIRCHEARTFAILURE.117.004361</Citation></Reference><Reference><Citation>Nunes MCP, Beaton A, Acquatella H, Bern C, Bolger AF, Echeverr&#xed;a LE, et al. Chagas cardiomyopathy: An update of current clinical knowledge and management: A scientific statement from the American Heart Association. Circulation 2018;138:e169&#x2013;e209. https://doi.org/10.1161/CIR.0000000000000599</Citation></Reference><Reference><Citation>Vilas Boas LG, Bestetti RB, Otaviano AP, Cardinalli&#x2010;Neto A, Nogueira PR. Outcome of Chagas cardiomyopathy in comparison to ischemic cardiomyopathy. Int J Cardiol 2013;167:486&#x2013;490. https://doi.org/10.1016/j.ijcard.2012.01.033</Citation></Reference><Reference><Citation>Lopes RD, Gimpelewicz C, McMurray JJV. Chagas disease: Still a neglected emergency? Lancet 2020;395:1113&#x2013;1114. https://doi.org/10.1016/S0140&#x2010;6736(20)30171&#x2010;9</Citation></Reference><Reference><Citation>Marin&#x2010;Neto JA, Rassi A Jr, Oliveira GMM, LCL C, Ramos J&#xfa;nior AN, Luquetti AO, et al. SBC guideline on the diagnosis and treatment of patients with cardiomyopathy of Chagas disease&#xa0;&#x2013;&#xa0;2023. Arq Bras Cardiol 2023;120:e20230269. https://doi.org/10.36660/abc.20230269</Citation></Reference><Reference><Citation>Rohde LEP, Montera MW, Bocchi EA, Clausell NO, Albuquerque DC, Rassi S, et al.; Comite Coordenador da Diretriz de Insuficiencia Cardiaca. Diretriz Brasileira de Insufici&#xea;ncia Card&#xed;aca Cr&#xf4;nica e Aguda. Arq Bras Cardiol 2018;111:436&#x2013;539. https://doi.org/10.5935/abc.20180190</Citation></Reference><Reference><Citation>McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al.; PARADIGM&#x2010;HF Investigators and Committees. Angiotensin&#x2010;neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993&#x2013;1004. https://doi.org/10.1056/NEJMoa1409077</Citation></Reference><Reference><Citation>Ramires FJA, Martinez F, Gomez EA, Demacq C, Gimpelewicz CR, Rouleau JL, et al. Post hoc analyses of SHIFT and PARADIGM&#x2010;HF highlight the importance of chronic Chagas' cardiomyopathy. Comment on: &#x201c;Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: A post hoc analysis of the SHIFT trial&#x201d; by Bocchi et al. ESC Heart Fail 2018;5:1069&#x2013;1071. https://doi.org/10.1002/ehf2.12355</Citation></Reference><Reference><Citation>Bocchi EA, Echeverria LE, Demacq C, PGM d BES, Mazza Barbosa L, et al.; PARACHUTE&#x2010;HF Investigators. Sacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy: Rationale and design of the PARACHUTE&#x2010;HF trial. JACC Heart Fail 2024;12:1473&#x2013;1486. https://doi.org/10.1016/j.jchf.2024.05.021</Citation></Reference><Reference><Citation>Hansson L, Hedner T, Dahlof B. Prospective randomized open blinded end&#x2010;point (PROBE) study. A novel design for intervention trials. Prospective randomized open blinded end&#x2010;point. Blood Press 1992;1:113&#x2013;119. https://doi.org/10.3109/08037059209077502</Citation></Reference><Reference><Citation>McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz M, Rizkala AR, et al.; PARADIGM&#x2010;HF Committees Investigators. Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM&#x2010;HF). Eur J Heart Fail 2014;16:817&#x2013;825. https://doi.org/10.1002/ejhf.115</Citation></Reference><Reference><Citation>Krum H, McMurray JJ, Abraham WT, Dickstein K, K&#xf8;ber L, Desai AS, et al.; ATMOSPHERE Committees and Investigators. The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): Revised statistical analysis plan and baseline characteristics. Eur J Heart Fail 2015;17:1075&#x2013;1083. https://doi.org/10.1002/ejhf.408</Citation></Reference><Reference><Citation>McMurray JJV, DeMets DL, Inzucchi SE, K&#xf8;ber L, Kosiborod MN, Langkilde AM, et al.; DAPA&#x2010;HF Committees and Investigators. The Dapagliflozin And Prevention of Adverse&#x2010;outcomes in Heart Failure (DAPA&#x2010;HF) trial: Baseline characteristics. Eur J Heart Fail 2019;21:1402&#x2013;1411. https://doi.org/10.1002/ejhf.1548</Citation></Reference><Reference><Citation>Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al.; EMPEROR&#x2010;Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383:1413&#x2013;1424. https://doi.org/10.1056/NEJMoa2022190</Citation></Reference><Reference><Citation>Teerlink JR, Diaz R, Felker GM, JJV MM, Metra M, Solomon SD, et al.; GALACTIC&#x2010;HF Investigators. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC&#x2010;HF baseline characteristics and comparison with contemporary clinical trials. Eur J Heart Fail 2020;22:2160&#x2013;2171. https://doi.org/10.1002/ejhf.2015</Citation></Reference><Reference><Citation>Silva PGMBE, Albuquerque DC, Lopes RD, Nogueira PR, Freitas AF Jr, Nascimento CV, et al. Acute heart failure in patients with Chagas cardiomyopathy: Results of the I Brazilian Heart Failure Registry (BREATHE). Arq Bras Cardiol 2025;122:e20240555. https://doi.org/10.36660/abc.20240555</Citation></Reference><Reference><Citation>Bloom MW, Greenberg B, Jaarsma T, Januzzi JL, CSP L, Maggioni AP, et al. Heart failure with reduced ejection fraction. Nat Rev Dis Primers 2017;3:17058. https://doi.org/10.1038/nrdp.2017.58</Citation></Reference><Reference><Citation>Morillo CA, Marin&#x2010;Neto JA, Avezum A, Sosa&#x2010;Estani S, Rassi A Jr, Rosas F, et al.; BENEFIT Investigators. Randomized trial of benznidazole for chronic Chagas' cardiomyopathy. N Engl J Med 2015;373:1295&#x2013;1306. https://doi.org/10.1056/NEJMoa1507574</Citation></Reference><Reference><Citation>Echeverria LE, Rojas LZ, Gomez&#x2010;Ochoa SA. Coagulation disorders in Chagas disease: A pathophysiological systematic review and meta&#x2010;analysis. Thromb Res 2021;201:73&#x2013;83. https://doi.org/10.1016/j.thromres.2021.02.025</Citation></Reference><Reference><Citation>Kristensen SL, Castagno D, Shen L, Jhund PS, Docherty KF, R&#xf8;rth R, et al.; PARADIGM&#x2010;HF and ATMOSPHERE Committees and Investigators. Prevalence and incidence of intra&#x2010;ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: Insights from PARADIGM&#x2010;HF and ATMOSPHERE. Eur J Heart Fail 2020;22:2370&#x2013;2379. https://doi.org/10.1002/ejhf.1972</Citation></Reference><Reference><Citation>Rojas LZ, Glisic M, Pletsch&#x2010;Borba L, Echeverr&#xed;a LE, Bramer WM, Bano A, et al. Electrocardiographic abnormalities in Chagas disease in the general population: A systematic review and meta&#x2010;analysis. PLoS Negl Trop Dis 2018;12:e0006567. https://doi.org/10.1371/journal.pntd.0006567</Citation></Reference><Reference><Citation>de Sousa AS, Vermeij D, Ramos AN Jr, Luquetti AO. Chagas disease. Lancet 2024;403:203&#x2013;218. https://doi.org/10.1016/S0140&#x2010;6736(23)01787&#x2010;7</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>